Clinical trials: PET/CT
Neuroendocrine Tumors
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
The aim of this study is to evaluate the potential of Al18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide (Al18F-NOTA-octreotide) as a positron emission tomography (PET) somatostatin receptor imaging agent in patients with…
- Trial name
- NCT03883776
- Testing
- Al18F-NOTA-octreotide, PET/CT, Venous blood samples
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cancer
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell…
- Trial name
- NCT07724535
- Testing
- 18F-grazy-02
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
Inhalant Use Disorder
Brain Imaging Studies of the Effect of Inhalant Use Disorder
Inhalants substance misuse is an important public health problem whose prevalence is approximately 1% in the general population and 7% among high school students in Mexico.
- Trial name
- NCT02188914
- Testing
- Positron emission tomography scan, Magnetic resonance imaging
- Where
- Mexico
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Miguel Ángel Mendoza Meléndez
Neoplasms
68Ga-P3 PET/CT Imaging in Malignancy
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a…
- Trial name
- NCT05887687
- Testing
- [68Ga]P3
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Positron-Emission Tomography
Dynamic FDG PET/CT: Optimization and Validation of Data Acquisition
Quantification of the metabolic rate of glucose from Dynamic Whole-Body PET examinations requires measurements of the time course of the radioactivity concentrations in arterial blood by blood sampling, and in the tissue of…
- Trial name
- VALIDATE (NCT04660279)
- Testing
- Dynamic Whole-Body parametric PET/CT
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Cholestasis, Genetic Liver Disorder
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals
Purpose The primary goal is to study liver diseases with defects in bile excretion. Investigators aim to do this using a radioactive tracer that mimics human bile and can be visualized with a PET/CT scanner.
- Trial name
- NCT06610695
- Where
- Denmark
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Tumor, Positron-Emission Tomography
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-BNU-PSMA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.
- Conditions
- Tumor, Positron-Emission Tomography, Metastasis
- Trial name
- NCT04525612
- Testing
- 68Ga-BNU-PSMA
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer, PET/CT
Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [68Ga]Ga-PSMA-D5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of…
- Trial name
- NCT05955677
- Testing
- [68Ga]Ga-PSMA-D5, [68Ga]Ga-PSMA-11
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Alpha Synuclein Pathology, Alpha-Synuclein
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.
- Conditions
- Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
- Trial name
- NCT06949670
- Testing
- 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT
Comparative Evaluation of Contrast-Enhanced MRI and FDG-PET/CT in Spinal Pathology: Image Quality and Short-Term Renal-Hematologic Safety
This prospective comparative observational study evaluates image quality characteristics and short-term physiological effects associated with contrast-enhanced magnetic resonance imaging (MRI) and fluorodeoxyglucose positron…
- Conditions
- Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT, Spinal Pathology
- Trial name
- NCT07640386
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cairo University
Head and Neck Cancer, Benign Neoplasm
Role of PET/MRI in Head and Neck Cancer
Study aim was to investigate the diagnostic role of Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) in head and neck cancer.
- Conditions
- Head and Neck Cancer, Benign Neoplasm, Malignant Neoplasm
- Trial name
- NCT04360993
- Testing
- Radiotherapy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Pecs
Neurodegenerative Disease, Alzheimer s Disease
[18F]NIDF PET Imaging in Tau-related Diseases
In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body.
- Conditions
- Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
- Trial name
- NCT07306598
- Where
- 3 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Cancer, FAP
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
To evaluate the potential usefulness of 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging （PET/MR）for the diagnosis of primary and metastatic…
- Trial name
- NCT06557590
- Testing
- 18F-FAPI-04
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hunan Cancer Hospital
Diagnostic Imaging
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
- Trial name
- NCT01009359
- Testing
- F-18 DPA-714 (BAY85-8102)
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Kidney Disease
Evaluation of Kidney Fibrosis Via FAPI PET/CT
Interstitial fibrosis is a hallmark of progression in chronic kidney disease (CKD), yet it can presently be assessed only by kidney biopsy, which is invasive and prone to sampling error.
- Trial name
- NCT07712679
- Testing
- PET/CT scan
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Prostate Cancer
Preoperative PSMA PET/CT As Triage for EPLND in Patients Scheduled for RALP (PrePSMA)
Extended pelvic lymph node dissection (ePLND) is considered the gold standard for nodal staging in men with prostate cancer (PCa).
- Trial name
- PrePSMA (NCT06398613)
- Testing
- extended pelvic lymph node dissection (ePLND)
- Where
- Norway
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Prostate Cancer, PET/CT
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of…
- Trial name
- NCT06462508
- Testing
- [18F]F-PSMA-N5, [68Ga]Ga-PSMA-11
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Gastrointestinal Cancer
Study of 18F-FAPI Applied to Gastrointestinal Cancer
Comparison of tumor volume, number, and SUVmax of different primary foci (gastric, duodenal, and colon cancer), lymph node metastases (neck and supraclavicular, mediastinal, abdominal, and pelvic), and distant metastases (brain…
- Trial name
- NCT05788874
- Testing
- 18F-FAPI and 18F-FDG PET/CT
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
PET/CT Imaging, NSCLC
Study on c-Met Targeted PET/CT Imaging in NSCLC
The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.
- Trial name
- NCT06911697
- Testing
- 18F-TSPF PET/CT
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Xilin Sun
Malignancies, Stomach Cancer
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can predict the efficacy and adverse events of apatinib in patients with malignancies.
- Conditions
- Malignancies, Stomach Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT03384511
- Testing
- Apatinib
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute